Adjuvant endocrine therapy in premenopausal women with breast cancer

[1] Goldhirsch A(2009)Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319-1329

[2] Ingle JN(2009)Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer J Surg Oncol 100 248-251

[3] Gelber RD(2006)NCCN task force report: adjuvant therapy for breast cancer J Natl Compr Canc Netw 4 S1-S28

[4] Coates AS(2007)Consenso en el tratamiento hormonal adyuvante del cáncer de mama de pacientes premenopáusicas Curr Opin Oncol 19 S25-S35

[5] Thurlimann B(2002)Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database Breast Cancer Res Treat 76 27-36

[6] Senn HJ(2000)Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355 1869-1874

[7] Bharat A(2001)Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer J Natl Cancer Inst Monogr 30 62-66

[8] Aft RL(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[9] Gao F(2008)aTTom (adjuvant tamoxifen—to offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results ASCO Meet Abstr 26 513-350

[10] Margenthaler JA(2007)ATLAS (adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results Breast Cancer Res Treat 106 1-1723

[1] Goldhirsch A(2009)Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 1319-1329

[2] Ingle JN(2009)Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer J Surg Oncol 100 248-251

[3] Gelber RD(2006)NCCN task force report: adjuvant therapy for breast cancer J Natl Compr Canc Netw 4 S1-S28

[4] Coates AS(2007)Consenso en el tratamiento hormonal adyuvante del cáncer de mama de pacientes premenopáusicas Curr Opin Oncol 19 S25-S35

[5] Thurlimann B(2002)Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database Breast Cancer Res Treat 76 27-36

[6] Senn HJ(2000)Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355 1869-1874

[7] Bharat A(2001)Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer J Natl Cancer Inst Monogr 30 62-66

[8] Aft RL(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[9] Gao F(2008)aTTom (adjuvant tamoxifen—to offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results ASCO Meet Abstr 26 513-350

[10] Margenthaler JA(2007)ATLAS (adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results Breast Cancer Res Treat 106 1-1723